Late-Breaking Science

Saturday, Nov. 16, 10:45 a.m. – 12:00 p.m.

• DAPA-HF - Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF): Results in Nondiabetic Patients
   
• ORION-10 - Phase 3 Trial Results: Safety and Efficacy of Inclisiran in Patients with ASCVD and Elevated LDL Cholesterol
   
• COLCOT - The Colchicine Cardiovascular Outcomes Trial in Coronary Disease
   
• BETonMACE - Effect of BET Protein Inhibition with Apabetalone on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Diabetes
   

Saturday, Nov. 16, 2:00 p.m. – 3:15 p.m.

• ISCHEMIA - International Study of Comparative Health Effectiveness with Medical and Invasive Approaches: Primary Report of Clinical Outcomes
   
• ISCHEMIA - International Study of Comparative Health Effectiveness with Medical and Invasive Approaches: Primary Report of Quality of Life Outcomes
   
• ISCHEMIA-CKD - International Study of Comparative Health Effectiveness with Medical and Invasive Approaches in Chronic Kidney Disease (ISCHEMIA-CKD): Primary Results of Clinical Outcomes

Saturday, Nov. 16, 5:30 p.m. – 6:45 p.m.

• GALILEO - Primary results: Global Comparison of a Rivaroxaban-based Antithrombotic Strategy Versus an Antiplatelet-based Strategy after Transcathether Aortic Valve Replacement to Optimize Clinical Outcomes
   
• GALILEO-4D - Randomized Clinical Trial Comparing a Rivaroxaban-based Strategy with an Antiplatelet-based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves
   
• Balloon-expandable versus Self-expandable TAVR on Paravalvular Regurgitation and 2-year Mortality: A Propensity-matched Comparison from The France-TAVI Registry
   
• RECOVERY - Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis

Sunday, Nov. 17, 9:00 a.m. – 10:15 a.m.

• TWILIGHT-ACS - Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention for Acute Coronary Syndrome
   
• COLCHICINE-PCI - Peri-procedural Colchicine in Percutaneous Coronary Intervention
   
• OCT COMPLETE - Non-culprit Lesion Plaque Morphology in Patients with ST-segment Elevation Myocardial Infarction: Substudy from the Complete Trial using Optical Coherence Tomography
   
• COACT - One Year Outcomes of Coronary Angiography After Cardiac Arrest
   
• Comparative Effectiveness and Costs of Impella versus Intra-aortic Balloon Pump in the United States

Sunday, Nov. 17, 10:45 a.m. – 12:00 p.m.

• FUEL - Longitudinal Results from the Pediatric Heart Network: Effect of Udenafil on Exercise Performance after Fontan
   
• DAPA-HF - Effect of Treatment Based on Age in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure
   
• DAPA-HF - Effect of treatment measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure
   
• PARAGON-HF - Effects of Sacubitril/valsartan in Women Compared to Men with Heart Failure and Preserved Ejection Fraction
   
• PARAGON-HF Secondary Analysis - Effect of Sacubitril/valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Monday, Nov. 18, 9:00 a.m. – 10:15 a.m.

• EVAPORATE - Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients on Statin Therapy with Elevated Triglycerides (200-499mg/dl)
   
• ORION-9 - Safety and Efficacy of Inclisiran in Patients with Heterozygous Familial Hypercholesterolemia
   
• RNA Interference Targeting Apolipoprotein C-III in Healthy Adults, Those Having Severe Hypertriglyceridemia and in Familial Chylomicronemia Syndrome
   
• Results Using RNA Interference to Target Hepatic Angiopoietin-like Protein 3 in Prolonging Reductions in Plasma Triglycerides and LDL-C in Humans
   
• Treat Stroke to Target - Benefit of a Target LDL Cholesterol Less than 70 mg/dl After Ischemic Stroke due to Atherosclerosis